(CEVI) CellaVision - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000683484
CEVI: Hematology Instruments, Analyzers, Software, Reagents, Blood Analysis
CellaVision AB is a Swedish company operating at the intersection of healthcare and technology, specializing in blood and body fluid analysis. Their core focus is on automating and digitizing hematology workflows, which is critical as labs worldwide look to enhance efficiency and accuracy. The company has built a suite of products that cater to both high-volume and low-volume laboratories, ensuring scalability across different market needs.
Their product lineup includes the CellaVision DM1200 and DM9600, which automate blood and body fluid differential analysis—two of the most time-consuming processes in hematology labs. These systems are designed to reduce manual labor and improve consistency in results. For smaller labs, the DC-1 analyzer makes digital hematology accessible without the need for high throughput, which is a smart move to capture market share in smaller facilities.
Beyond hardware, CellaVision has developed a range of software solutions that add significant value. Their Peripheral Blood Application standardizes smear reviews, while the Advanced RBC Application provides deeper insights into red blood cell morphology. These tools are particularly useful for labs looking to maintain high diagnostic standards without relying on overly skilled technicians. The Remote Review Software is another standout, enabling labs to outsource smear reviews to specialists regardless of location—a feature that’s increasingly important in a globalized healthcare system.
What’s often overlooked is their proficiency and training tools. The CellaVision Proficiency Software helps labs assess and improve their staff’s competency, which is a hidden driver of customer retention. Similarly, their CellAtlas platform combines educational content with a vast image library, serving as both a training tool and a reference database. This approach not only helps labs adopt their technology but also builds a moat around their customer base.
Financially, CellaVision trades with a market cap of 4,889.56M SEK and a
Additional Sources for CEVI Stock
CEVI Stock Overview
| Market Cap in USD | 439m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
CEVI Stock Ratings
| Growth 5y | -44.5% |
| Fundamental | 70.9% |
| Dividend | 54.3% |
| Rel. Strength Industry | -26.1 |
| Analysts | - |
| Fair Price Momentum | 153.95 SEK |
| Fair Price DCF | 60.04 SEK |
CEVI Dividends
| Dividend Yield 12m | 1.05% |
| Yield on Cost 5y | 0.78% |
| Annual Growth 5y | 31.61% |
| Payout Consistency | 83.9% |
CEVI Growth Ratios
| Growth Correlation 3m | -42.2% |
| Growth Correlation 12m | -27.3% |
| Growth Correlation 5y | -56.8% |
| CAGR 5y | -8.46% |
| CAGR/Max DD 5y | -0.11 |
| Sharpe Ratio 12m | -0.58 |
| Alpha | -36.64 |
| Beta | 0.51 |
| Volatility | 44.87% |
| Current Volume | 22.5k |
| Average Volume 20d | 62.6k |
As of February 22, 2025, the stock is trading at SEK 186.00 with a total of 22,460 shares traded.
Over the past week, the price has changed by -5.10%, over one month by -19.83%, over three months by -13.29% and over the past year by -24.40%.
Yes, based on ValueRay Fundamental Analyses, CellaVision (ST:CEVI) is currently (February 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 70.93 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CEVI as of February 2025 is 153.95. This means that CEVI is currently overvalued and has a potential downside of -17.23%.
CellaVision has no consensus analysts rating.
According to ValueRays Forecast Model, CEVI CellaVision will be worth about 177.8 in February 2026. The stock is currently trading at 186.00. This means that the stock has a potential downside of -4.4%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 242.5 | 30.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 177.8 | -4.4% |